Health News Releases

  • Today May 15
March 17, 2021 14:35
Grand Prize Winners Selected in $6M XPRIZE Rapid Covid Testing Competition to Create Fast, Frequent, Cheap, and Easy-to-Use Solutions
XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, is pleased to announce today the five winning teams in the $6M XPRIZE Rapid Covid Tes
March 17, 2021 11:55
PCI Pharma Broadens Clinical Trial Service Offerings at Berlin Facility, Bringing Worldwide Access to Clients in the European Union
PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced a new milestone in its global Clinical footprint with the expansion of
March 17, 2021 10:40
Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders
Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on the development of novel centrally acting COMT (catec
March 16, 2021 15:35
Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utili
March 16, 2021 12:05
Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection (Refractory, With or Without Resistance)
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today during the Presidential Symposium at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EB
March 16, 2021 10:00
New Study Evaluates the Ability of Masimo EMMA® Capnography to Assess the Respiratory Status of Children With Tracheostomy
Masimo (NASDAQ: MASI) today announced the findings of an observational, retrospective study published in Pediatrics International. In the study, researchers at the Osaka Women’s and Children’s Hospita
March 15, 2021 12:00
Landmark Long-Term Data from EORTC’s MINDACT Study Published in The Lancet Oncology
Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that long-term follow up data from MINDACT, the prospective, randomized trial designed to further confirm the cli
March 12, 2021 18:55
Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade[1]
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (“GEM BU
March 12, 2021 17:10
Humanigen Announces $80 Million Loan Facility from Hercules Capital
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidat
March 12, 2021 17:07
Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan fo
March 12, 2021 15:05
Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidat
March 11, 2021 19:40
Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire Maverick Therapeutics, Inc. a private biopharmaceutical company pioneering co
March 11, 2021 17:30
Korea’s Ministry of Health and Welfare and KHIDI Announce Medical Korea 2021 Virtual Conference: “Global Healthcare, Where Your Days Begin Again”
The upcoming Medical Korea 2021, the 11th Global Healthcare and Medical Tourism Conference, is being held virtually to discuss the latest healthcare trends and forecasts, to share Korea’s advancing me
March 10, 2021 13:55
Tanner Pharma Group Expands Ex-US Access Program to Provide LEUKINE® for Use in Patients with Respiratory Illness Associated with COVID-19
Tanner Pharma Group (Tanner) today announced expansion of the LEUKINE Access Program (LeAP) as a channel for distribution of LEUKINE® (sargramostim) in international markets. LEUKINE®, approved by the
March 10, 2021 11:20
Covetrus Announces Vice President of Global Talent Management
Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the addition of Stacey M.M. Shirra as vice president of global talent management. The newly created p
March 09, 2021 18:55
Cell Therapy for Cartilage Regeneration Gets a Boost With Hyaluronic Acid Enriched Chondrocytes in a 3D Tissue Engineering Platform
Regenerative therapy to treat knee joint damages gets a boost with a breakthrough technology of growing ideal type of cartilage cells including chondroprogenitors and mesenchymal stem cells enriched w
March 09, 2021 17:25
Masimo Monitoring Solutions Promote Newborn and Maternal Safety
Masimo (NASDAQ: MASI) provides a variety of innovative monitoring solutions designed to improve maternal and newborn safety during childbirth and the critical first minutes of life. Masimo SET® pulse
March 08, 2021 15:37
Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
Regulatory News: Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug A
March 08, 2021 13:10
TrakCel Fuels Growth and Increased Market Access Through Strategic Investment Round
TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces that it has closed its latest funding round led by AmerisourceBergen and
March 08, 2021 11:20
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform th
March 08, 2021 09:40
LSK Global PS Adopts Veeva Vault Clinical Applications to Streamline Global Trial Processes
Veeva Systems (NYSE: VEEV) announced that LSK Global Pharma Services Co. Ltd, a leading Korean contract research organization (CRO), has adopted Veeva Vault eTMF, Veeva Vault CTMS, and Veeva SiteVault
March 05, 2021 14:50
COVID-19 Vaccine Adjuvant Potentials of Nichi Glucan Dietary Supplement From Japan
ß- glucan produced by AFO-202 strain of black yeast Aureobasidium Pullulans (Nichi Glucan), having immune enhancement potentials through all major pathways, has been recommended worth clinical studies
March 04, 2021 19:15
PierianDx Announces the Appointment of Lindsay Mateo as Chief Business Officer
PierianDx, the global leader in clinical genomics knowledge, today announced the appointment of Lindsay Mateo as Chief Business Officer, effective immediately. In her new role, Ms. Mateo will reinforc
March 04, 2021 17:58
Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe
Galderma today announced a European re-launch of Sculptra® (injectable poly-L-lactic acid) - a collagen stimulator - with an updated administration protocol. This means that the product is ready for u
March 03, 2021 18:45
Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth[1]
Regulatory News: Vifor Pharma Group reported stable net sales and a continued strong increase in profitability in 2020, despite challenges to patient access from COVID-19 and the impact of a much s
25 per page50 per page75 per page100 per page